by Clinical Neuropsychologist Online | Tuesday, July 28, 2026 | Dementia
Abstract In response to a Cochrane review (published in April 2026) on the clinical trials of monoclonal antibodies targeting beta amyloid, this perspective outlines a number of critiques. The scientists, methodologists, subject-matter experts, and clinicians on this...
by Clinical Neuropsychologist Online | Tuesday, July 28, 2026 | Dementia
Abstract Cochrane Reviews are widely regarded as the gold standard for evidence synthesis, yet analytical framing influences interpretation. A recent Cochrane review of amyloid beta–targeting monoclonal antibodies pools mechanistically and biologically heterogenous...
by Clinical Neuropsychologist Online | Tuesday, July 28, 2026 | Dementia
Abstract INTRODUCTION Data are needed to inform best practices for disclosing apolipoprotein E (APOE) results given increasing indications for testing. METHODS CONNECT4, a multi-center, randomized trial (NCT02978729) compared disclosure of APOE genotype by...
by Clinical Neuropsychologist Online | Tuesday, July 28, 2026 | Dementia
Abstract INTRODUCTION Cognitive impairment among older adults is often due to multiple pathologies and heterogenous risk factors. We assessed whether Alzheimer’s blood-based biomarkers (BBMs) were associated with incident mild cognitive impairment (MCI)/probable...
by Clinical Neuropsychologist Online | Tuesday, July 28, 2026 | Dementia
ABSTRACT INTRODUCTION The relationships between superficial white matter (SWM) and cognition, and its interaction with gray matter (GM), remain unclear in community-based populations. METHODS We analyzed data from 459 older adults in the Harmonized Diagnostic...
